RxDoctor Payments Data

Meghan Bonds, MD

Family Medicine · Greensboro, ALNPI 1477089217

Payments from drug & device makers

$978in general payments, 2019–2025

Across 46 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$322
  • Novartis$205
  • AstraZeneca$146
  • Lilly USA, LLC$76
  • Johnson & Johnson$52
  • AbbVie$48
  • plus $131 from 5 others

What the payments were for

  • Food & beverage$978100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$978 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$15,159
Medicare patients
100
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$143,700
FarxigaDapagliflozin Propanediol110$104,278
EliquisApixaban99$76,284
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$55,703
RybelsusSemaglutide38$54,378
MounjaroTirzepatide29$44,618
JardianceEmpagliflozin45$43,648
EntrestoSacubitril/Valsartan23$24,121
XareltoRivaroxaban23$21,350
LinzessLinaclotide21$16,885
TrulicityDulaglutide14$16,827
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$14,906
Tresiba Flextouch U-200Insulin Degludec11$11,202
JanumetSitagliptin Phos/Metformin Hcl14$9,339
MyrbetriqMirabegron15$7,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$322$198,078117 claims
AstraZenecaFarxiga, Breztri Aerosphere$146$119,185123 claims
PfizerEliquis$13$76,28499 claims
Lilly USA, LLCMounjaro, Trulicity$76$61,44543 claims
NovartisEntresto$205$24,12123 claims
Johnson & JohnsonXarelto$52$21,35023 claims
AbbVieLinzess$48$16,88521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Greensboro

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →